Developer docs
API playgroundTry for free, no card

Search company profiles

Corvus Pharmaceuticals

Full company profile

uuid0002e57

Namestring
Corvus Pharmaceuticals
Legal namestring
Corvus Pharmaceuticals, Inc.
Company typeenum
Public
Founded yearint
2014
Descriptiontext

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in South San Francisco, California, with 51–100 employees. The company is developing a pipeline of investigational immunotherapies for cancer and immune-mediated diseases, anchored by soquelitinib (CPI-818), a first-in-class oral small molecule that selectively inhibits interleukin-2-inducible T-cell kinase (ITK). ITK inhibition modulates T-cell differentiation, skewing responses toward Th1 helper cells while suppressing Th2 and Th17 pathways. The pipeline also includes ciforadenant (CPI-444), an oral adenosine A2a receptor antagonist designed to block immunosuppressive signaling in the tumor microenvironment, and mupadolimab (CPI-006), an anti-CD73 antibody that reduces adenosine production while activating B cells.

Soquelitinib is being evaluated across a broad set of indications: a Phase 3 trial in relapsed/refractory peripheral T-cell lymphoma, Phase 2 trials in atopic dermatitis, asthma, and hidradenitis suppurativa, and combination work in renal cell carcinoma. Phase 1 atopic dermatitis data have shown 75% EASI-75 response rates, a 72% mean EASI reduction versus 40% for placebo, and no rebound during drug-free follow-up up to 90 days. Corvus holds a 49% equity stake in Angel Pharmaceuticals, a China-focused joint venture co-founded in 2020 that is running parallel atopic dermatitis and asthma trials in China.

The company is pre-revenue and has generated no product sales through fiscal 2025. Capital is raised through public equity markets; in January 2026 Corvus closed a $201.2 million upsized underwritten offering (led by Jefferies and Goldman Sachs), bringing cash and marketable securities to approximately $236.7 million at the end of Q1 2026 and extending the runway into Q2 2028. R&D expenses were $33.7 million in FY2025. Revenue, when it materializes, will come from prescription drug sales, supplemented by potential royalties or milestones from the Angel Pharmaceuticals partnership.

Short descriptiontext

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing soquelitinib, a first-in-class oral ITK inhibitor for T-cell lymphomas and inflammatory diseases, alongside adenosine-pathway oncology assets, with no product revenue and a cash runway into Q2 2028.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBurlingame, United States
HQ citystring
Burlingame
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
clinical-stage biopharmaceuticals, immuno-oncology therapeutics, ITK inhibitor platform, cancer immunotherapy drugs, inflammatory disease therapies
Industry2 codes
PRIMARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAL
Dermatology Specialty Pharmaceuticals
NAICS code3 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Clinical-stage Immuno-oncology Therapeutics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Product Revenue
TypeOne Time License
Description

Currently pre-revenue clinical-stage company. No commercialized products. Revenue will come from drug sales upon regulatory approval.

2Licensing/Partnership Revenue
TypeLicensing Royalties
Description

Potential future revenue from licensing agreements, such as partnership with Angel Pharmaceuticals for development in China.

Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Soquelitinib (CPI-818)
Description

Lead product candidate - first-in-class, oral therapy that selectively inhibits ITK to modulate and control parallel signaling pathways in the immune system

corvuspharma.com
+2 more records
Core offering1 text field

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing investigational small-molecule and antibody immunotherapies that modulate T-cell signaling and the adenosine pathway for the treatment of immune diseases and cancer. Its lead asset, soquelitinib (CPI-818), is a first-in-class oral selective ITK inhibitor in Phase 3 for peripheral T-cell lymphoma and Phase 2 for atopic dermatitis, supported by ciforadenant (CPI-444), an oral A2a receptor antagonist, and mupadolimab (CPI-006), an anti-CD73 antibody.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 75% of patients achieved EASI 75 in Phase 1 atopic dermatitis trial (cohort 4)
+2 more records
Product overview1 text field

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing a pipeline of investigational medicines for immune diseases and cancer. The company's core portfolio consists of three clinical-stage programs: soquelitinib (CPI-818), an oral ITK inhibitor in Phase 3 for peripheral T-cell lymphoma and Phase 2 for atopic dermatitis; ciforadenant (CPI-444), an oral A2a receptor antagonist checkpoint inhibitor; and mupadolimab (CPI-006), an anti-CD73 antibody. Soquelitinib is the lead program, a first-in-class selective ITK inhibitor that modulates T cell signaling pathways. The other two programs target the adenosine pathway through different mechanisms. The company also has a partnership with Angel Pharmaceuticals for development in China.

Product and service3 records
1Soquelitinib (CPI-818)
CategoryClinical-stage ITK inhibitor immunotherapy
Description

Investigational first-in-class oral small molecule that selectively inhibits ITK (interleukin-2-inducible T cell kinase), affecting T cell differentiation by inducing Th1 helper cells while blocking Th2 and Th17 cells. Being developed for T-cell lymphomas, atopic dermatitis, asthma, and hidradenitis suppurativa.

2Ciforadenant (CPI-444)
CategoryClinical-stage adenosine pathway immunotherapy
Description

Investigational small molecule, oral checkpoint inhibitor designed to block adenosine binding to immune cells in the tumor microenvironment by targeting the A2a receptor, disabling tumors' ability to subvert immune attack.

3Mupadolimab (CPI-006)
CategoryClinical-stage adenosine pathway immunotherapy
Description

Investigational anti-CD73 antibody that blocks adenosine production in the tumor microenvironment and binds to B cells, activating and differentiating them into antibody-producing plasma cells, augmenting both cellular and humoral immunity.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-09
Description

Corvus co-founded Angel Pharma in 2020 and holds 49% equity stake. Angel Pharma is conducting Phase 1b/2 trial of soquelitinib for atopic dermatitis and a new Phase 2 trial for asthma in China. Initial atopic dermatitis results expected late 2026, asthma trial launching early 2027. Corvus invested $5 million in June 2026 $13.5M financing round.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage oncology company developing small-molecule and antibody programs against the adenosine pathway (CD73, A2a receptor), directly overlapping with Corvus's ciforadenant and mupadolimab programs in mechanism and indication.

2Innate Pharma
TypeDirect peer
Description

Clinical-stage immunology company developing adenosine-pathway and innate-immune targeted antibodies and NK-cell engagers, with overlap to Corvus's adenosine-pathway strategy and T-cell-directed immunomodulation pipeline.

TypeDirect peer
Description

Computational-immunology biotech developing novel immuno-oncology targets for cancer, with a therapeutic focus area and clinical-stage pipeline that overlaps Corvus's tumor-microenvironment-directed approach.

TypeEmerging player
Description

Clinical-stage biotech developing tumor-activated immunotherapies including T-cell engagers and INDUCER molecules, comparable to Corvus as a small-cap, oncology-focused immunotherapy developer with selective mechanism-based assets.

5Surface Oncology
TypeDirect peer
Description

Clinical-stage immuno-oncology company focused on targeting the tumor microenvironment via novel mechanisms, including myeloid and T-cell modulators, broadly comparable to Corvus's adenosine-pathway and ITK programs.

TypeEmerging player
Description

Clinical-stage biotech developing small-molecule modulators of the TGF-beta superfamily for hematology and immunology, comparable to Corvus as a focused clinical-stage immunology and inflammation company.

7ChemoCentryx (Amgen)
TypeBroad incumbent
Description

Now part of Amgen following acquisition, ChemoCentryx pioneered oral small-molecule inhibitors of complement and chemoattractant receptors for immune diseases — the same 'small molecule replacing injectable biologic' positioning Corvus is pursuing with soquelitinib in atopic dermatitis.

TypeBroad incumbent
Description

Markets Dupixent (dupilumab), the dominant injectable biologic in moderate-to-severe atopic dermatitis. As Corvus's soquelitinib targets the same indication with an oral, first-in-class ITK mechanism, Regeneron is the most relevant competitive incumbent.

TypeBroad incumbent
Description

Markets Rinvoq (upadacitinib), a leading oral JAK inhibitor in atopic dermatitis, and Skyrizi, providing direct competitive context for Corvus's oral soquelitinib positioning in the same disease.

TypeBroad incumbent
Description

Markets Cibinqo (abrocitinib) and multiple other oral JAK inhibitors in atopic dermatitis, establishing the bar for Corvus's soquelitinib oral ITK inhibitor program in this competitive multi-modality indication.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles13 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors19 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment1 record

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Corvus Pharmaceuticals

Clinical-stage Immuno-oncology Therapeuticscorvuspharma.com

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing soquelitinib, a first-in-class oral ITK inhibitor for T-cell lymphomas and inflammatory diseases, alongside adenosine-pathway oncology assets, with no product revenue and a cash runway into Q2 2028.

What Corvus Pharmaceuticals does

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is a clinical-stage biopharmaceutical company founded in 2014 and headquartered in South San Francisco, California, with 51–100 employees. The company is developing a pipeline of investigational immunotherapies for cancer and immune-mediated diseases, anchored by soquelitinib (CPI-818), a first-in-class oral small molecule that selectively inhibits interleukin-2-inducible T-cell kinase (ITK). ITK inhibition modulates T-cell differentiation, skewing responses toward Th1 helper cells while suppressing Th2 and Th17 pathways. The pipeline also includes ciforadenant (CPI-444), an oral adenosine A2a receptor antagonist designed to block immunosuppressive signaling in the tumor microenvironment, and mupadolimab (CPI-006), an anti-CD73 antibody that reduces adenosine production while activating B cells.

Soquelitinib is being evaluated across a broad set of indications: a Phase 3 trial in relapsed/refractory peripheral T-cell lymphoma, Phase 2 trials in atopic dermatitis, asthma, and hidradenitis suppurativa, and combination work in renal cell carcinoma. Phase 1 atopic dermatitis data have shown 75% EASI-75 response rates, a 72% mean EASI reduction versus 40% for placebo, and no rebound during drug-free follow-up up to 90 days. Corvus holds a 49% equity stake in Angel Pharmaceuticals, a China-focused joint venture co-founded in 2020 that is running parallel atopic dermatitis and asthma trials in China.

The company is pre-revenue and has generated no product sales through fiscal 2025. Capital is raised through public equity markets; in January 2026 Corvus closed a $201.2 million upsized underwritten offering (led by Jefferies and Goldman Sachs), bringing cash and marketable securities to approximately $236.7 million at the end of Q1 2026 and extending the runway into Q2 2028. R&D expenses were $33.7 million in FY2025. Revenue, when it materializes, will come from prescription drug sales, supplemented by potential royalties or milestones from the Angel Pharmaceuticals partnership.

Corvus Pharmaceuticals firmographics

Firmographics
Name
Corvus Pharmaceuticals
Legal name
Corvus Pharmaceuticals, Inc.
Website
https://corvuspharma.com
Company type
Public
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing soquelitinib, a first-in-class oral ITK inhibitor for T-cell lymphomas and inflammatory diseases, alongside adenosine-pathway oncology assets, with no product revenue and a cash runway into Q2 2028.
Ownership category
akta.pro rank

Corvus Pharmaceuticals industry classification

Industry
Product category
Clinical-stage Immuno-oncology Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAC
Cytokines, Interferons & Immunomodulatory Proteins
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAIACAL
Dermatology Specialty Pharmaceuticals

Keywords

  • Clinical-stage biopharmaceuticals
  • Immuno-oncology therapeutics
  • ITK inhibitor platform
  • Cancer immunotherapy drugs
  • Inflammatory disease therapies

Where Corvus Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Burlingame
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Corvus Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

  1. Product Revenue: Currently pre-revenue clinical-stage company. No commercialized products. Revenue will come from drug sales upon regulatory approval.
  2. Licensing/Partnership Revenue: Potential future revenue from licensing agreements, such as partnership with Angel Pharmaceuticals for development in China.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Corvus Pharmaceuticals product offering

Product offering

Core offering

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing investigational small-molecule and antibody immunotherapies that modulate T-cell signaling and the adenosine pathway for the treatment of immune diseases and cancer. Its lead asset, soquelitinib (CPI-818), is a first-in-class oral selective ITK inhibitor in Phase 3 for peripheral T-cell lymphoma and Phase 2 for atopic dermatitis, supported by ciforadenant (CPI-444), an oral A2a receptor antagonist, and mupadolimab (CPI-006), an anti-CD73 antibody.

Product overview

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing a pipeline of investigational medicines for immune diseases and cancer. The company's core portfolio consists of three clinical-stage programs: soquelitinib (CPI-818), an oral ITK inhibitor in Phase 3 for peripheral T-cell lymphoma and Phase 2 for atopic dermatitis; ciforadenant (CPI-444), an oral A2a receptor antagonist checkpoint inhibitor; and mupadolimab (CPI-006), an anti-CD73 antibody. Soquelitinib is the lead program, a first-in-class selective ITK inhibitor that modulates T cell signaling pathways. The other two programs target the adenosine pathway through different mechanisms. The company also has a partnership with Angel Pharmaceuticals for development in China.

Differentiator

Problem solved

Functional benefit

Brands

  • Soquelitinib (CPI-818): Lead product candidate - first-in-class, oral therapy that selectively inhibits ITK to modulate and control parallel signaling pathways in the immune system
  • Ciforadenant (CPI-444)
  • Mupadolimab (CPI-006)

Products and services

  • Soquelitinib (CPI-818) Investigational first-in-class oral small molecule that selectively inhibits ITK (interleukin-2-inducible T cell kinase), affecting T cell differentiation by inducing Th1 helper cells while blocking Th2 and Th17 cells. Being developed for T-cell lymphomas, atopic dermatitis, asthma, and hidradenitis suppurativa.
  • Ciforadenant (CPI-444) Investigational small molecule, oral checkpoint inhibitor designed to block adenosine binding to immune cells in the tumor microenvironment by targeting the A2a receptor, disabling tumors' ability to subvert immune attack.
  • Mupadolimab (CPI-006) Investigational anti-CD73 antibody that blocks adenosine production in the tumor microenvironment and binds to B cells, activating and differentiating them into antibody-producing plasma cells, augmenting both cellular and humoral immunity.

Quantifiable outcome

  • 75% of patients achieved EASI 75 in Phase 1 atopic dermatitis trial (cohort 4)
  • +2 more outcomes

Companies that use Corvus Pharmaceuticals

Customer profile

Segments3 records

Ideal customer profiles1 record

Corvus Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Corvus Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Angel Pharmaceuticals Ltd.coreStrategic or Co-development Partner · 9 June 2026Corvus co-founded Angel Pharma in 2020 and holds 49% equity stake. Angel Pharma is conducting Phase 1b/2 trial of soquelitinib for atopic dermatitis and a new Phase 2 trial for asthma in China. Initial atopic dermatitis results expected late 2026, asthma trial launching early 2027. Corvus invested $5 million in June 2026 $13.5M financing round.

Scale indicators8 records

Recent moves6 records

Expansion highlights5 records

Corvus Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Arcus Biosciences: Clinical-stage oncology company developing small-molecule and antibody programs against the adenosine pathway (CD73, A2a receptor), directly overlapping with Corvus's ciforadenant and mupadolimab programs in mechanism and indication.
  • Innate Pharma: Clinical-stage immunology company developing adenosine-pathway and innate-immune targeted antibodies and NK-cell engagers, with overlap to Corvus's adenosine-pathway strategy and T-cell-directed immunomodulation pipeline.
  • Compugen: Computational-immunology biotech developing novel immuno-oncology targets for cancer, with a therapeutic focus area and clinical-stage pipeline that overlaps Corvus's tumor-microenvironment-directed approach.
  • Surface Oncology: Clinical-stage immuno-oncology company focused on targeting the tumor microenvironment via novel mechanisms, including myeloid and T-cell modulators, broadly comparable to Corvus's adenosine-pathway and ITK programs.

Emerging players

  • Werewolf Therapeutics: Clinical-stage biotech developing tumor-activated immunotherapies including T-cell engagers and INDUCER molecules, comparable to Corvus as a small-cap, oncology-focused immunotherapy developer with selective mechanism-based assets.
  • Keros Therapeutics: Clinical-stage biotech developing small-molecule modulators of the TGF-beta superfamily for hematology and immunology, comparable to Corvus as a focused clinical-stage immunology and inflammation company.

Broad incumbents

  • ChemoCentryx (Amgen): Now part of Amgen following acquisition, ChemoCentryx pioneered oral small-molecule inhibitors of complement and chemoattractant receptors for immune diseases — the same 'small molecule replacing injectable biologic' positioning Corvus is pursuing with soquelitinib in atopic dermatitis.
  • Regeneron Pharmaceuticals: Markets Dupixent (dupilumab), the dominant injectable biologic in moderate-to-severe atopic dermatitis. As Corvus's soquelitinib targets the same indication with an oral, first-in-class ITK mechanism, Regeneron is the most relevant competitive incumbent.
  • AbbVie: Markets Rinvoq (upadacitinib), a leading oral JAK inhibitor in atopic dermatitis, and Skyrizi, providing direct competitive context for Corvus's oral soquelitinib positioning in the same disease.
  • Pfizer: Markets Cibinqo (abrocitinib) and multiple other oral JAK inhibitors in atopic dermatitis, establishing the bar for Corvus's soquelitinib oral ITK inhibitor program in this competitive multi-modality indication.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

Corvus Pharmaceuticals social profiles

Digital presence

Corvus Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Corvus Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles13 records

Corvus Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Corvus Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Corvus Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Corvus Pharmaceuticals

What does Corvus Pharmaceuticals do?

Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company developing investigational small-molecule and antibody immunotherapies that modulate T-cell signaling and the adenosine pathway for the treatment of immune diseases and cancer. Its lead asset, soquelitinib (CPI-818), is a first-in-class oral selective ITK inhibitor in Phase 3 for peripheral T-cell lymphoma and Phase 2 for atopic dermatitis, supported by ciforadenant (CPI-444), an oral A2a receptor antagonist, and mupadolimab (CPI-006), an anti-CD73 antibody.

Is Corvus Pharmaceuticals a public or private company?

Corvus Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was Corvus Pharmaceuticals founded?

Corvus Pharmaceuticals was founded in 2014. It employs 51 to 100 people.

Where is Corvus Pharmaceuticals based?

Corvus Pharmaceuticals is headquartered in Burlingame, United States, in the North America region.

How does Corvus Pharmaceuticals make money?

Two revenue lines are on record. Product Revenue is the primary driver. The others are licensing/Partnership Revenue.

Who are Corvus Pharmaceuticals's main competitors?

Direct peers on record are Arcus Biosciences, Innate Pharma, Compugen and Surface Oncology. Emerging players are Werewolf Therapeutics and Keros Therapeutics. Broad incumbents are ChemoCentryx (Amgen), Regeneron Pharmaceuticals, AbbVie and Pfizer.

Does Corvus Pharmaceuticals have an API?

No public API is recorded for Corvus Pharmaceuticals.

What industry is Corvus Pharmaceuticals in?

Corvus Pharmaceuticals's product category is Clinical-stage Immuno-oncology Therapeutics. Its primary akta.pro industry code is HLAAAAAC, Cytokines, Interferons & Immunomodulatory Proteins, with a secondary code of HLAIACAL, Dermatology Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market News1,040,606 Shares in Corvus Pharmaceuticals, Inc. $CRVS Acquired by Fisher Asset Management LLCFisher Asset Management acquired a new stake in Corvus Pharmaceuticals, buying 1,040,606 shares valued at about $11.99 million. The stake represents roughly 1.24% of the company, and institutional investors hold 46.64% of the stock. Analysts have a consensus rating of Moderate Buy with an average price target of $32.83.Seeking AlphaCorvus Pharmaceuticals: Durability, Not Peak Efficacy, Is The Real Product (NASDAQ:CRVS)Corvus Pharmaceuticals' soquelitinib is highlighted for durable remission in atopic dermatitis and PTCL, with a fully funded pipeline through Q2 2028. Major readouts including SIERRA-1 and PTCL Phase 3 are expected within this runway, reducing near-term financing risk. The stock trades at a 4.27x price-to-book premium, viewed as a well-capitalized platform investment.Business & FinancialCorvus Pharmaceuticals To Present At The 2026 Jefferies Global Healthcare Conference In LondonCorvus Pharmaceuticals will present at the 2026 Jefferies Global Healthcare Conference in London, with a webcast available for 90 days. The company's lead candidate, soquelitinib, is being evaluated in Phase 3 for relapsed/refractory peripheral T cell lymphoma and Phase 2 for atopic dermatitis.American Banking and Market NewsCorvus Pharmaceuticals (NASDAQ:CRVS) Stock Dropped to “Strong Sell” by Wall Street ZenWall Street Zen downgraded Corvus Pharmaceuticals to a strong sell rating, while other firms have mixed ratings. The stock opened at $10.54, and the company reported Q2 EPS of -$0.22, missing the -$0.19 consensus. Analysts forecast a -0.79 EPS for the current fiscal year.The Motley FoolCorvus (CRVS) Q3 2026 Earnings Call TranscriptCorvus Pharmaceuticals reported a Q3 2026 net loss of $20.3 million and R&D expenses of $17.8 million, with cash of $202.9 million. The company advanced its soquelitinib pipeline, including a Phase 3 PTCL trial with a futility analysis expected in Q1 2027 and a Phase 2 atopic dermatitis trial with top-line data anticipated in Q3 2027.The Motley FoolCorvus (CRVS) Q3 2026 Earnings Call TranscriptCorvus Pharmaceuticals reported Q3 2026 net loss of $20.3 million and R&D expenses of $17.8 million, with cash of $202.9 million. The company advanced its soquelitinib pipeline, including a Phase 3 PTCL trial with a futility analysis expected in Q1 2027 and a Phase 2 atopic dermatitis trial with top-line data anticipated in Q3 2027.Investing.comMizuho reiterates Corvus Pharmaceuticals stock rating on pipelineMizuho reiterated an Outperform rating and $27 price target on Corvus Pharmaceuticals after its Q3 results. The stock trades at $10.27, with a Strong Buy consensus. Corvus posted an adjusted EPS of -$0.22, missing the -$0.19 consensus, but holds $202.9 million in cash.YahooCorvus Pharmaceuticals Inc (CRVS) Q3 2026 Earnings Call Highlights: Strong Cash Runway and Key ...Corvus Pharmaceuticals reported a Q3 2026 net loss of $20.3 million, up from $10.2 million, with R&D expenses rising to $17.8 million. The company holds $202.9 million in cash, expected to fund operations into Q2 2028, and socolitinib trials are on track with top-line data expected by end of 2027.TradingViewCorvus Pharmaceuticals Q3 2026 Earnings Call Is LiveCorvus Pharmaceuticals's Q3 2026 earnings call is live, with executives discussing financial results and answering analyst questions. The call may include surprise news, and management commentary on demand, margins, or capital spending could move markets.Stock TitanCorvus Pharmaceuticals to Present 1-Year ALPS Trial DataCorvus Pharmaceuticals announced initial data from a Phase 2 trial of soquelitinib for autoimmune lymphoproliferative syndrome (ALPS), to be presented at the ASH meeting. Three patients completed one year of treatment with no grade 3 or 4 adverse events and discontinued background medications including steroids. The company plans to explore longer treatment durations and enroll younger pediatric patients.